Tigatuzumab, a human monoclonal antibody that acts as a death receptor 5 agonist, has shown preclinical promise in inducing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activity in tumor cells [54]. Here, TNFRSF10B is linked to neoplasm.